Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism

References

• Perera D, Yusof MA, Podin Y, et al. Molecular phylogeny of modern coxsackievirus A16. Arch Virol. 2007;152(6):1201–1208.
   PubMed Web of Science ®Google Scholar
• Cox B, Hand LF. Foot, and mouth disease. JAMA. 2018 Dec 18;320(23):2492.
   PubMedGoogle Scholar
• Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016 May;15(5):599–606.
   PubMed Web of Science ®Google Scholar
• Hosoya M, Kawasaki Y, Sato M, et al. Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J Clin Microbiol. 2007 Jan;45(1):112–120.
   PubMed Web of Science ®Google Scholar
• Iwai M, Masaki A, Hasegawa S, et al. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis. 2009 Jul;62(4):254–259.
   PubMed Web of Science ®Google Scholar
• Li L, He Y, Yang H, et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol. 2005 Aug;43(8):3835–3839.
   PubMed Web of Science ®Google Scholar
• Mutterer M Sicklesgm, Plager H Feorinop. Recently classified types of Coxsackie virus, group A; behavior in tissue culture. Proc Soc Exp Biol Med. 1955 Nov;90(2):529–531.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Yao X, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10(2):360–367.
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin TY, Huang YC, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999 Dec;18(12):1092–1096.
   PubMed Web of Science ®Google Scholar
• Goto K, Sanefuji M, Kusuhara K, et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009 Oct;15(10):1689–1691.
   PubMed Web of Science ®Google Scholar
• Ma S, Zhang Y, Du C, et al. Dynamic constitution of the pathogens inducing encephalitis in hand, foot and mouth disease in Kunming, 2009-2011. Jpn J Infect Dis. 2015;68(6):504–510.
   PubMed Web of Science ®Google Scholar
• Yao X, Mao Q, Li Y, et al. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo. Hum Vaccin Immunother. 2018 May 4;14(5):1275–1282.
   PubMed Web of Science ®Google Scholar
• Vogt MR, Dowd KA, Engle M, et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol. 2011 Nov;85(22):11567–11580.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Gao R, et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012 Nov;86(22):11967–11976.
   PubMed Web of Science ®Google Scholar
• Du R, Mao Q, Hu Y, et al. A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Hum Vaccin Immunother. 2019;15(10):2343–2350.
   PubMed Web of Science ®Google Scholar
• Ren J, Wang X, Zhu L, et al. Structures of Coxsackievirus A16 capsids with native antigenicity: implications for particle expansion, receptor binding, and immunogenicity. J Virol. 2015 Oct;89(20):10500–10511.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yan K, Feng Y, et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012 Oct 19;30(47):6642–6648.
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011 Dec 6;29(52):9668–9674.
   PubMed Web of Science ®Google Scholar
• A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Available from: http://www.wpro.who.int/publications/docs/Guidanceforthec linicalmanagementofHFMD.pdf.
   Google Scholar
• Japanese Encephalitis: Vaccine Preventable Diseases Surveillance Standards. Available from:https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-je.
   Google Scholar
• Takada A, Ebihara H, Jones S, et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007 Jan 22;25(6):993–999.
   PubMed Web of Science ®Google Scholar
• Chang LY, King CC, Hsu KH, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002 Jun;109(6):e88.
   PubMed Web of Science ®Google Scholar
• Jin J, Ma H, Xu L, et al. Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum. J Virol Methods. 2013 Feb;187(2):362–367.
   PubMed Web of Science ®Google Scholar
• Mizuta K, Abiko C, Murata T, et al. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol. 2005 Dec;43(12):6171–6175.
   PubMed Web of Science ®Google Scholar
• Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010 Feb;9(2):149–156.
   PubMed Web of Science ®Google Scholar
• Liu Q, Shi J, Huang X, et al. A murine model of coxsackievirus A16 infection for anti-viral evaluation. Antiviral Res. 2014 May;105:26–31.
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhao J, Zhao Y, et al. Hemagglutinin-specific non-neutralizing antibody is essential for protection provided by inactivated and viral-vectored H7N9 avian influenza vaccines in chickens. Front Vet Sci. 2020 Jan 9;6: 482.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Yu WH, Karim MM, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host Microbe. 2018 Aug 8;24(2):221–233. e5.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Gordan S, Lux A. Fcγr dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 2015 Jun;36(6):325–336.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020 Oct;20(10):633–643.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Tan GS, Palese P, et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014 Feb;20(2):143–151.
   PubMed Web of Science ®Google Scholar
• Ilinykh PA, Huang K, Santos RI, et al. Non-neutralizing antibodies from a marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe. 2020 Jun 10;27(6):976–991. e11.
   PubMed Web of Science ®Google Scholar
• Li C, Wang H, Shih SR, et al. The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Curr Med Chem. 2007;14(8):847–856.
   PubMed Web of Science ®Google Scholar
• Shi J, Huang X, Liu Q, et al. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013 Apr 19;31(17):2130–2136.
   PubMed Web of Science ®Google Scholar
• Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012 Mar 4;19(4):424–429.
   PubMed Web of Science ®Google Scholar
• Plevka P, Lim PY, Perera R, et al. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2134–2139.
   PubMed Web of Science ®Google Scholar
• Xu L, He D, Yang L, et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci Rep. 2015 Aug 5;5: 12973.
   Web of Science ®Google Scholar
• Plevka P, Perera R, Cardosa J, et al. Crystal structure of human enterovirus 71. Science. 2012 Jun 8;336(6086):1274.
   PubMed Web of Science ®Google Scholar
• Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011 Jun 10;29(26):4362–4372.
   PubMed Web of Science ®Google Scholar
• Xu L, He D, Li Z, et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014 Feb 18;4(5):498–513.
   PubMed Web of Science ®Google Scholar
• Kiener TK, Jia Q, Lim XF, et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J. 2012 Feb 24;9: 55.
   Web of Science ®Google Scholar
• Breschkin AM, Ahern J, White DO. Antigenic determinants of influenza virus hemagglutinin. VIII. topography of the antigenic regions of influenza virus hemagglutinin determined by competitive radioimmunoassay with monoclonal antibodies. Virology. 1981 Aug;113(1):130–140.
   PubMed Web of Science ®Google Scholar